Jurata’s thin film technology stabilizes vaccine and biologics at room temperature, even elevated temperatures. Additionally, thin film manufacturing does not require lyophilization and can be completed in 3-4 hours, potentially increasing pharmaceutical manufacturing efficiency. Vaccines and biologics stabilized in our thin film can be administered via sublingual, buccal, intranasal, or parenteral routes. This flexibility enables needle-free administration of vaccines and biologics. The combined benefits of our technology in pharmaceutical manufacturing, delivery, and access mean that our technology enables strategic pandemic preparedness for current and future public health crises.